Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study-Reference-Cited by-同舟云学术

Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study

Published:2023-07 Issue: Volume:383 Page:1-7
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Pompei Graziella,Campo Gianluca,Ruggiero Rossella,Maffeo Diego,Sgura Fabio,Arrotti Salvatore,Preti Gerlando,Iannaccone Mario,Erriquez Andrea,Biscaglia Simone,Sganzerla Paolo,Capecchi Alessandro,Pignatelli Gianluca,Dall'Ara Gianni,Saia Francesco,Tomassini Francesco,Rolfo Cristina,Varbella Ferdinando,Cerrato Enrico

Funder

Università degli Studi di Ferrara

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Stent-related adverse events >1 year after percutaneous coronary intervention;Madhavan;J. Am. Coll. Cardiol.,2020

2. Scaffold thrombosis after percutaneous coronary intervention with ABSORB Bioresorbable vascular scaffold: a systematic review and Meta-analysis;Lipinski;JACC Cardiovasc. Interv.,2016

3. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III;Haude;EuroIntervention.,2017

4. Sustained safety and performance of the second-generation Sirolimus-eluting absorbable metal scaffold: pooled outcomes of the BIOSOLVE-II and -III trials at 3 years;Haude;Cardiovasc. Revasc. Med.,2020

5. Sustained safety and performance of the second-generation Sirolimus-eluting absorbable metal scaffold: long-term data of the BIOSOLVE-II and -III trials at 5 years;Haude;Cardiovasc. Revasc. Med.,2022